Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039299 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00039299 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center.
The verdict
NCT00039299, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's T cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of T-cell therapy in treating patients who have prostate cancer that has not responded to hormone therapy.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Est. Completion | 2003-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039299
The ClinicalTrials.gov registry entry for NCT00039299 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which therapeutic autologous lymphocytes is the first listed.
NCT00039299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039299 about?
NCT00039299 is a clinical study titled "Biological Therapy in Treating Patients With Prostate Cancer". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's T cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectivene...
What is the current status of trial NCT00039299?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-03. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00039299?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00039299?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.